Lipid H5T5
Version 1.afeaa24e · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid H5T5 |
| Synonyms | LipidH5T5;Lipid-H5T5 |
| SMILES | CC(C)=CCC/C(C)=C/CC/C(C)=C/COC(=O)CCN(CCCN(C)C)CCCN(CCC(=O)OC/C=C(\C)CC/C=C(\C)CCC=C(C)C)CCC(=O)OC/C=C(\C)CC/C=C(\C)CCC=C(C)C |
| Formula | C62H105O6N3 |
| M.Wt | 988.54 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Lipid nanoparticle–mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy-Qimeng Yin, Xue Liang, Chenchen Zhang etl. PNAS 123 (8) e2509698123 |
H5T5 is a leading ionizable lipid nanoparticle (LNP) formulation optimized for in vivomRNA delivery, featuring a pKa of 6.51, a size of ~154 nm, and a narrow polydispersity index (PDI) of 0.05. It demonstrated superior in vitromRNA transfection efficiency in primary immune cells, such as bone marrow-derived macrophages. Following intravenous administration, H5T5 exhibits precise organotropism, predominantly targeting the spleen and bone marrow, where it effectively delivers mRNA to a broad spectrum of immune cells, including macrophages, dendritic cells, T cells, B cells, and NK cells. This capability enables its core application: the in vivogeneration of "pan-CAR" immune cells. When loaded with anti-HER2 CAR mRNA, the H5T5-based therapy achieved potent tumor regression and prolonged survival in multiple solid tumor models. Preliminary safety assessments indicated a manageable cytokine profile and no significant organ toxicity, positioning it as a promising platform for in vivocell engineering.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →